Sanara MedTech Inc. (SMTI)

Market Cap	294.49M
Revenue (ttm)	78.06M
Net Income (ttm)	-8.36M
Shares Out	8.74M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,324
Open	35.56
Previous Close	35.31
Day's Range	33.69 - 35.56
52-Week Range	26.00 - 39.98
Beta	1.57
Analysts	Strong Buy
Price Target	47.00 (+39.51%)
Earnings Date	Mar 24, 2025

About SMTI

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and pa...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 108
• Stock Exchange: NASDAQ
• Ticker Symbol: SMTI
• Website: https://sanaramedtech.com

Financial Performance

In 2023, Sanara MedTech's revenue was $64.99 million, an increase of 41.77% compared to the previous year's $45.84 million. Losses were -$4.30 million, -45.79% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for SMTI stock is "Strong Buy." The 12-month stock price forecast is $47.0, which is an increase of 39.51% from the latest price.

Price Target

$47.0

(39.51% upside)

Analyst Consensus: Strong Buy